Nautilus to Participate in the Morgan Stanley Global Healthcare Conference
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) will participate virtually at the Morgan Stanley Global Healthcare Conference on September 15, 2021, at 1:15 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) will participate virtually at the Morgan Stanley Global Healthcare Conference on September 15, 2021, at 1:15 p.m. ET. The event will feature a presentation detailing Nautilus' innovative single-molecule protein analysis platform that quantifies the human proteome. Attendees can access a live and archived webcast through Nautilus' website. The company aims to enhance basic science research and improve therapeutic development through its advanced proteomics technology.
Details
News Market Reaction – NAUT
The recorded move for NAUT in the trading session of this news was -3.27%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the human proteome, today announced the company will be participating virtually in the upcoming Morgan Stanley Global Healthcare Conference.
Nautilus’ management is scheduled to present on Wednesday, September 15th at 1:15 p.m. Eastern Time/10:15 a.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the company’s website at: https://www.nautilus.bio/investors/
About Nautilus Biotechnology, Inc.
Nautilus is a biotechnology company who is developing a proteomics platform that aims to deliver superior sensitivity more quickly, more completely, and less expensively than is currently possible. Nautilus Biotechnology aims to enable a dramatic acceleration of basic science research, significantly improve the success rate of therapeutic development, and enhance opportunities for personalized and predictive medicine. Nautilus’ corporate headquarters is in Seattle, Washington and scientific research and development is being conducted from its San Carlos, California office and labs.
Contacts
Investors:
InvestorRelations@nautilus.bio
Media:
Chris Blessington
Vice President, Corporate Marketing and Communications
chrisb@nautilus.bio
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.